The company posted loss of cents share in the latest quarter, seven cents wider than Wall Streets consensus forecast. Drugs are even more hitormiss business, and more miss than hit these days. Controversial biotech firm ImClone IMCL has been repeatedly accused of misleading investors as it shepherds muchdelayed cancer drug through the regulatory approval process. ImClone shares fell 13.. In the meantime, the red ink is spreading.

Drugs are even more hitormiss business, and more miss than hit these days. Controversial biotech firm ImClone IMCL has been repeatedly accused of misleading investors as it shepherds muchdelayed cancer drug through the regulatory approval process. In the meantime, the red ink is spreading. ImClone shares fell 13.. The company posted loss of cents share in the latest quarter, seven cents wider than Wall Streets consensus forecast.